Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
5001
AllianzIM U.S. Equity Buffer20 Oct ETF
OCTW
$320M
| $195 | ﹤0.01% |
+5
| New | +$193 |
2025 Q4
0 quarters
|
|
|
PEW
5002
GrabAGun Digital Holdings
PEW
$57M
| $181 | ﹤0.01% |
60
| – | – |
2025 Q3
1 quarter
|
|
5003
Chanson International
CHSN
$2.51M
| $169 | ﹤0.01% |
1
-6
| -86% | -$1.39K |
2025 Q3
1 quarter
|
|
5004
Genmab
GMAB
$21.7B
| $154 | ﹤0.01% |
5
| – | – |
2022 Q1
15 quarters
|
|
|
STKE
5005
Sol Strategies Inc
STKE
$67.9M
| $153 | ﹤0.01% |
100
-3,650
| -97% | -$10.6K |
2025 Q3
1 quarter
|
|
|
ABPWW
5006
DELISTED
Abpro Holdings Warrant
ABPWW
| $137 | ﹤0.01% |
8,333
-241,667
| -97% | -$4.59K |
2022 Q2
14 quarters
|
|
|
VELO
5007
Velo3D Inc
VELO
$360M
| $124 | ﹤0.01% |
9
| – | – |
2025 Q3
1 quarter
|
|
|
LPBBW
5008
Launch Two Acquisition Corp Warrant
LPBBW
$1.97M
| $123 | ﹤0.01% |
390
| – | – |
2024 Q4
4 quarters
|
|
|
OPI
5009
DELISTED
Office Properties Income Trust
OPI
| $103 | ﹤0.01% |
7,990
| – | – |
2019 Q1
27 quarters
|
|
|
TGE.WS
5010
The Generation Essentials Group Warrants
TGE.WS
| $103 | ﹤0.01% |
685
| – | – |
2025 Q2
2 quarters
|
|
|
LPSN
5011
DELISTED
LivePerson
LPSN
| $101 | ﹤0.01% |
26
-62
| -70% | -$345 |
2013 Q2
50 quarters
|
|
5012
Innovator US Equity Ultra Buffer ETF October
UOCT
$181M
| $78 | ﹤0.01% |
+2
| New | +$77 |
2025 Q4
0 quarters
|
|
5013
Fathom Holdings
FTHM
$11.4M
| $73 | ﹤0.01% |
72
| – | – |
2022 Q1
15 quarters
|
|
5014
Dyadic International
DYAI
$18.3M
| $68 | ﹤0.01% |
72
| – | – |
2020 Q2
22 quarters
|
|
|
ADAP
5015
DELISTED
Adaptimmune Therapeutics
ADAP
| $66 | ﹤0.01% |
2,532
-2
| -0.1% | – |
2023 Q2
10 quarters
|
|
5016
Q32 Bio
QTTB
$245M
| $63 | ﹤0.01% |
19
-803
| -98% | -$2.27K |
2018 Q2
30 quarters
|
|
5017
Invesco DB US Dollar Index Bullish Fund
UUP
$426M
| $54 | ﹤0.01% |
2
| – | – |
2023 Q1
11 quarters
|
|
5018
iShares 1-5 Year Investment Grade Corporate Bond ETF
IGSB
$23.6B
| $53 | ﹤0.01% |
1
| – | – |
2024 Q4
4 quarters
|
|
5019
iShares 10+ Year Investment Grade Corporate Bond ETF
IGLB
$2.48B
| $50 | ﹤0.01% |
1
| – | – |
2024 Q4
4 quarters
|
|
|
XELAP
5020
DELISTED
Exela Technologies, Inc. 6.00% Series B Cumulative Convertible Perpetual Preferred Stock
XELAP
| $50 | ﹤0.01% |
24,900
| – | – |
2024 Q4
4 quarters
|
|
5021
MiNK Therapeutics
INKT
$63.5M
| $45 | ﹤0.01% |
+4
| New | +$52 |
2025 Q4
0 quarters
|
|
|
ZSQR
5022
Z Squared Inc
ZSQR
$210M
| $43 | ﹤0.01% |
3
| – | – |
2022 Q4
12 quarters
|
|
5023
FT Vest US Equity Deep Buffer ETF March
DMAR
$469M
| $42 | ﹤0.01% |
1
-4,921
| -100% | -$202K |
2025 Q2
2 quarters
|
|
|
HIMX
5024
Himax Technologies
HIMX
$2.66B
| $41 | ﹤0.01% |
+5
| New | +$42 |
2025 Q4
0 quarters
|
|
5025
Tenaris
TS
$28.3B
| $38 | ﹤0.01% |
1
| – | – |
2022 Q1
15 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.